NTLA Nasdaq In Vitro & In Vivo Diagnostic Substances Financials FY2016βFY2025
Intellia Therapeutics, Inc. had $67.7M of revenue in fiscal 2025, up 16.9% on the year before. Over five years, revenue changed +3.1% a year on average.
Last close Β· Oct 23, 2026
$11.21
0.4%Hi! I read Intellia Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+16.9%
Yes. Sales grew 16.9% last year.
Does it make a profit?
β609.9%
No. It lost money last year.
Does profit turn into cash?
β585.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Intellia Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | Before the market opens | 8-K β |
| Apr 27, 2026 | Q1 '26 | Time not announced | 8-K β |
| Feb 26, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 6, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 7, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 8, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Jan 9, 2025 | Q4 '24 | Time not announced | 8-K β |
| Nov 7, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Intellia Therapeutics, Inc. had $67.7M of revenue in fiscal 2025, up 16.9% on the year before. Over five years, revenue changed +3.1% a year on average. Its operating margin was β651.7%, up 271.4Β pts: of every 100 in sales, about β652 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Intellia Therapeutics, Inc. lost $413M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$396M in fiscal 2025, β585.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Intellia Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $749M | $1.2B | $912M | $602M | $450M |
| Current ratio | 6.1x | 9.6x | 8.7x | 5.8x | 5.1x |
| Quick ratio | 6.1x | 9.6x | 8.7x | 5.8x | 5.1x |
| Total assets | $1.3B | $1.5B | $1.3B | $1.2B | $842M |
| Total liabilities | $254M | $285M | $251M | $319M | $171M |
| Shareholders' equity | $1.0B | $1.2B | $1.1B | $872M | $671M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Intellia Therapeutics, Inc. passes 2 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 2 / 7 | 4 / 8 | 3 / 8 | 1 / 8 | 3 / 7 | 1 / 7 | 2 / 7 | 2 / 7 |
| Accruals ratio | β22.7% | β0.7% | β6.7% | β108.8% | β16.7% | β4.3% | β10.0% | β6.2% | β13.7% | β1.8% |
| Altman Z'' | 6.66 | 7.52 | 5.93 | 4.31 | 5.61 | 4.40 | 4.71 | 2.03 | β3.19 | β6.12 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Gross profit | β | β | $30.4M | $43.1M | $58.0M | $33.1M | β | β | β | β |
| Research and development | $31.8M | $67.6M | $89.1M | $108M | $150M | $230M | $420M | $435M | $466M | $389M |
| Operating income | β$32.2M | β$69.6M | β$90.9M | β$106M | β$137M | β$268M | β$458M | β$515M | β$534M | β$441M |
| Pretax income | β$31.6M | β$67.5M | β | β | β | β | β | β | β | β |
| Income tax | $0.0M | β | β | β | β | β | β | β | β | $0.0M |
| Net income | β$31.6M | β$67.5M | β$85.3M | β$474M | β$134M | β$268M | β$474M | β$481M | β$519M | β$413M |
| Diluted EPS | β$1.42 | β$1.88 | β$1.98 | β$2.11 | β$2.40 | β$3.78 | β$6.16 | β$5.42 | β$5.25 | β$3.81 |
| Diluted shares | 0.02B | 0.04B | 0.04B | 0.00B | 0.06B | 0.07B | 0.08B | 0.09B | 0.10B | 0.11B |
| Cash flow | ||||||||||
| Cash from operations | $36.1M | β$65.3M | β$61.3M | β$103M | β$49.9M | β$225M | β$333M | β$394M | β$349M | β$395M |
| Capital expenditure | $6.2M | $10.1M | $6.4M | $6.8M | $3.6M | $12.8M | $13.6M | $14.0M | $5.8M | $1.1M |
| Free cash flow | $29.9M | β$75.4M | β$67.6M | β$110M | β$53.5M | β$238M | β$347M | β$408M | β$355M | β$396M |
| Depreciation and amortization | $1.1M | $3.0M | $4.5M | $5.6M | $6.3M | $6.9M | $7.6M | $9.0M | $10.3M | $9.8M |
| Stock-based compensation | $6.7M | $15.3M | $17.0M | $15.1M | $19.9M | $47.0M | $91.4M | $134M | $154M | $80.2M |
| Acquisitions | β | β | β | β | β | β | $0.3M | $0.3M | $0.3M | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $273M | $341M | $314M | $280M | $597M | $749M | $1.2B | $912M | $602M | $450M |
| Current assets | $281M | $355M | $325M | $289M | $617M | $769M | $1.2B | $998M | $640M | $528M |
| Current liabilities | $30.7M | $31.4M | $40.6M | $35.6M | $64.3M | $126M | $127M | $115M | $111M | $104M |
| Property and equipment, net | $10.6M | $15.3M | $17.1M | $18.0M | $15.9M | $21.0M | $27.9M | $32.8M | $27.4M | $17.7M |
| Total assets | $299M | $376M | $347M | $334M | $676M | $1.3B | $1.5B | $1.3B | $1.2B | $842M |
| Total liabilities | $89.1M | $75.6M | $69.4M | $64.4M | $149M | $254M | $285M | $251M | $319M | $171M |
| Shareholders' equity | $210M | $301M | $278M | $270M | $527M | $1.0B | $1.2B | $1.1B | $872M | $671M |
| Margins | ||||||||||
| Gross margin | β | β | 100.0% | 100.0% | 100.0% | 100.0% | β | β | β | β |
| Operating margin | β195.2% | β266.3% | β298.6% | β246.8% | β235.5% | β810.4% | β879.0% | β1,420.5% | β923.1% | β651.7% |
| EBITDA margin | β188.5% | β254.9% | β283.9% | β233.8% | β224.6% | β789.5% | β864.5% | β1,395.8% | β905.3% | β637.2% |
| Net margin | β192.0% | β258.6% | β280.4% | β1,100.1% | β231.5% | β810.5% | β909.8% | β1,326.5% | β896.8% | β609.9% |
| FCF margin | 181.7% | β288.6% | β222.2% | β255.3% | β92.2% | β719.4% | β665.5% | β1,124.9% | β612.8% | β585.0% |
| Returns | ||||||||||
| Return on capital employed | β12.0% | β20.2% | β29.6% | β35.6% | β22.3% | β22.9% | β32.9% | β43.5% | β49.5% | β59.7% |
| Return on equity | β15.1% | β26.5% | β29.5% | β173.1% | β33.7% | β34.2% | β41.7% | β42.1% | β54.0% | β53.5% |
| Return on assets | β10.6% | β20.0% | β23.6% | β139.1% | β26.6% | β27.2% | β33.7% | β34.1% | β41.7% | β40.6% |
| Return on tangible equity | β15.1% | β22.5% | β30.7% | β175.7% | β25.5% | β25.8% | β38.4% | β45.8% | β59.5% | β61.5% |
| Growth | ||||||||||
| Revenue growth | β | 58.5% | 16.5% | 41.6% | 34.5% | β43.0% | 57.7% | β30.4% | 59.6% | 16.9% |
| FCF growth | β | β351.7% | β | β | β | β | β | β | β | β |
| Share count change | β | 62.0% | 19.6% | β99.9% | 118,516.5% | 26.6% | 8.6% | 15.3% | 11.4% | 9.6% |
| Financial health | ||||||||||
| Current ratio | 9.2x | 11.3x | 8.0x | 8.1x | 9.6x | 6.1x | 9.6x | 8.7x | 5.8x | 5.1x |
| Quick ratio | 9.2x | 11.3x | 8.0x | 8.1x | 9.6x | 6.1x | 9.6x | 8.7x | 5.8x | 5.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 37.4% | 38.6% | 20.9% | 15.8% | 6.2% | 38.6% | 26.0% | 38.6% | 10.0% | 1.7% |
| Stock comp / revenue | 40.7% | 58.7% | 56.0% | 35.0% | 34.3% | 142.2% | 175.4% | 369.5% | 266.6% | 118.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 2.0 | 4.0 | 3.0 | 1.0 | 3.0 | 1.0 | 2.0 | 2.0 |
| Altman Z'' | 6.7 | 7.5 | 5.9 | 4.3 | 5.6 | 4.4 | 4.7 | 2.0 | β3.2 | β6.1 |
| Accruals ratio | β22.7% | β0.7% | β6.7% | β108.8% | β16.7% | β4.3% | β10.0% | β6.2% | β13.7% | β1.8% |
Source: SEC EDGAR XBRL filings (CIK 0001652130). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
